» Articles » PMID: 25986647

Buprenorphine Treatment and 12-step Meeting Attendance: Conflicts, Compatibilities, and Patient Outcomes

Overview
Specialty Psychiatry
Date 2015 May 20
PMID 25986647
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

This analysis examines patient experiences and outcomes with 12-step recovery group attendance during buprenorphine maintenance treatment (BMT), two approaches with traditionally divergent philosophies regarding opioid medications for treatment of opioid use disorder. Using quantitative (n = 300) and qualitative (n = 20) data collected during a randomized trial of counseling services in buprenorphine treatment, this mixed-methods analysis of African Americans in BMT finds the number of NA meetings attended in the prior 6 months was associated with a higher rate of retention in BMT (p < .001) and heroin/cocaine abstinence at 6 month follow-up (p = .005). However, patients whose counselors required them to attend 12-step meetings did not have better outcomes than patients not required to attend such meetings. Qualitative narratives highlighted patients' strategies for managing dissonant viewpoints on BMT and disclosing BMT status in community 12-step meetings. Twelve-step meeting attendance is associated with better outcomes for BMT patients over the first 6 months of treatment. However, there is no benefit to requiring meeting attendance as a condition of treatment, and clinicians should be aware of potential philosophical conflicts between 12-step and BMT approaches.

Citing Articles

PROTOCOL: Mutual Help Organizations to Support Recovery Among Individuals Who Use Drugs: A Systematic Review Protocol.

Hennessy E, Bergman B, Levine L, OConnor J, Klein M, Kelly J Campbell Syst Rev. 2025; 21(1):e70021.

PMID: 40041478 PMC: 11876998. DOI: 10.1002/cl2.70021.


"There's always somebody that you can identify with": a qualitative study of patient perspectives on buprenorphine group medical visits.

Masyukova M, Hayes B, Lopez-Castro T, Fox A Addict Sci Clin Pract. 2025; 20(1):8.

PMID: 39910610 PMC: 11796086. DOI: 10.1186/s13722-025-00540-7.


Narrative review: Managing buprenorphine and opioid use disorder in the perioperative setting.

Kohan L, Barreveld A, Potru S, Abd-Elsayed A, Viscusi E Pain Pract. 2024; 25(1):e13427.

PMID: 39450825 PMC: 11683522. DOI: 10.1111/papr.13427.


Buprenorphine use among non-hospital residential programs.

Nichols C, Baslock D, Sieger M Drug Alcohol Depend. 2024; 264:112456.

PMID: 39369475 PMC: 11527563. DOI: 10.1016/j.drugalcdep.2024.112456.


Linkage facilitation for opioid use disorder in criminal legal system contexts: a primer for researchers, clinicians, and legal practitioners.

Satcher M, Belenko S, Coetzer-Liversage A, Wilson K, McCart M, Drazdowski T Health Justice. 2024; 12(1):36.

PMID: 39207608 PMC: 11363440. DOI: 10.1186/s40352-024-00291-8.


References
1.
. What is recovery? A working definition from the Betty Ford Institute. J Subst Abuse Treat. 2007; 33(3):221-8. DOI: 10.1016/j.jsat.2007.06.001. View

2.
Clausen T, Anchersen K, Waal H . Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend. 2007; 94(1-3):151-7. DOI: 10.1016/j.drugalcdep.2007.11.003. View

3.
Gryczynski J, Jaffe J, Schwartz R, Dusek K, Gugsa N, Monroe C . Patient perspectives on choosing buprenorphine over methadone in an urban, equal-access system. Am J Addict. 2013; 22(3):285-91. PMC: 4215541. DOI: 10.1111/j.1521-0391.2012.12004.x. View

4.
Kelly J, Stout R, Slaymaker V . Emerging adults' treatment outcomes in relation to 12-step mutual-help attendance and active involvement. Drug Alcohol Depend. 2012; 129(1-2):151-7. PMC: 3566342. DOI: 10.1016/j.drugalcdep.2012.10.005. View

5.
Pollack H, DAunno T . Dosage patterns in methadone treatment: results from a national survey, 1988-2005. Health Serv Res. 2008; 43(6):2143-63. PMC: 2613988. DOI: 10.1111/j.1475-6773.2008.00870.x. View